Affiliations 

  • 1 Grupo Oncoclínicas de Pesquisa em Oncologia, Hospital São Lucas, PUCRS, Porto Alegre, Brazil. barrios@thummi.global
  • 2 Division of Medical Oncology, Sylvester Comprehensive Cancer Center at the University of Miami and the Miller School of Medicine, Miami, FL, USA. glopes.md@gmail.com
  • 3 Pantai Cancer Institute, Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia. drmasturamy@pantai.com.my
  • 4 Department of Oncology, Rwanda Military Hospital, Kigali, Rwanda. fidel.rubagumya@queensu.ca
  • 5 Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland. Piotr.Rutkowski@pib-nio.pl
  • 6 Department of Medical Oncology, Tata Memorial Centre affiliated to Homi Bhabha National Institute, Mumbai, India. manju.sengar@gmail.com
Nat Rev Clin Oncol, 2023 Jan;20(1):7-15.
PMID: 36380066 DOI: 10.1038/s41571-022-00700-7

Abstract

In the past decade, oncologists worldwide have seen unprecedented advances in drug development and approvals but have also become increasingly cognizant of the rising costs of and increasing inequities in access to these therapies. These trends have resulted in the current problematic situation in which dramatic disparities in outcomes exist among patients with cancer worldwide owing, in part, to the lack of access to drugs that provide clinically meaningful benefits. In this Viewpoint, we have asked six oncologists working in different countries to describe how they perceive this issue in their region and propose potential solutions.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.